[177Lu]Lu-DOTA-ZOL 治疗多癌种骨转移骨痛:疗效与安全性
本研究纳入 40 例因多癌种骨转移而骨痛的患者,接受平均累积剂量 2.1±0.6 GBq(1.3-2.7 GBq)的[177Lu]Lu-DOTA-ZOL 治疗,中位随访 10 个月(IQR 8-14 个月)。VAS 评估总缓解率达 90%,VAS、镇痛评分及 ECOG 状态较基线显著改善,未出现 III/IV 级血液、肾或肝毒性。
要点
- VAS 评估完全、部分、轻微缓解分别为 27.5%、50%、12.5%,总缓解率 90%。
- VAS、镇痛评分及 ECOG 状态较基线显著改善。
- 无患者出现治疗相关 III/IV 级血液、肾或肝毒性。
核心结论
- [177Lu]Lu-DOTA-ZOL 对多癌种骨转移所致骨痛有效,且安全性良好。
研究设计与样本
- 单臂研究纳入 40 例因骨转移骨痛的患者,接受平均累积剂量 2.1±0.6 GBq(1.3-2.7 GBq)的[177Lu]Lu-DOTA-ZOL 治疗,中位随访 10 个月(IQR 8-14 个月)。
主要发现
- VAS 评估完全、部分、轻微缓解分别为 11 例(27.5%)、20 例(50%)、5 例(12.5%),总缓解率 90%。
- 全局疼痛评估完全、部分、轻微、无缓解分别为 2 例(5%)、25 例(62.5%)、9 例(22.5%)、4 例(10%)。
- VAS、镇痛评分及 ECOG 状态较基线显著改善。
- 无患者出现[177Lu]Lu-DOTA-ZOL 治疗相关 III/IV 级血液、肾或肝毒性。
关键数值与推荐
- VAS 缓解评估标准下总缓解率为 90%。
- 安全性按美国国家癌症研究所常见毒性标准 V5.0 评估,未报告 III/IV 级血液、肾或肝毒性。
临床怎么用
- 对于多癌种骨转移所致骨痛患者,[177Lu]Lu-DOTA-ZOL 可作为镇痛治疗选择,需按 VAS 等指标评估疗效并监测毒性。
局限性
- 单臂设计、样本量 40 例,缺乏对照组,疗效结论需更大规模对照研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: [177Lu]Lu-DOTA-ZOL has shown promising results from the dosimetry and preclinical aspects, but data on its role in the clinical efficacy are limited. The objective of this study is to evaluate the efficacy and safety of [177Lu]Lu-DOTA-ZOL as a bone pain palliation agent in patients experiencing pain due to skeletal metastases from various cancers. METHODS: In total, 40 patients experiencing bone pain due to skeletal metastases were enrolled in this study. The patients were treated with a mean cumulative dose of 2.1 ± 0.6 GBq (1.3-2.7 GBq) [177Lu]Lu-DOTA-ZOL in a median follow-up duration of 10 months (IQR 8-14 months). The primary outcome endpoint was response assessment according to the visual analogue score (VAS). Secondary endpoints included analgesic score (AS), global pain assessment score, Eastern Cooperative Oncology Group Assessment performance status (ECOG), Karnofsky performance status, overall survival, and safety assessment by the National Cancer Institute's Common Toxicity Criteria V5.0. RESULTS: In total, 40 patients (15 males and 25 females) with a mean age of 46.6 ± 15.08 years (range 24-78 years) were treated with either 1 (N = 15) or 2 (N = 25) cycles of [177Lu]Lu-DOTA-ZOL. According to the VAS response assessment criteria, complete, partial, and minimal responses were observed in 11 (27.5%), 20 (50%), and 5 patients (12.5%), respectively with an overall response rate of 90%. Global pain assessment criteria revealed complete, partial, minimal, and no response in 2 (5%), 25 (62.5%), 9 (22.5%), and 4 (10%) patients, respectively. Twenty-eight patients died and the estimated median overall survival was 13 months (95% CI 10-14 months). A significant improvement was observed in the VAS, AS, and ECOG status when compared to baseline. None of the patients experienced grade III/IV haematological, kidney, or hepatotoxicity due to [177Lu]Lu-DOTA-ZOL therapy. CONCLUSION: [177Lu]Lu-DOTA-ZOL shows promising results and is an effective radiopharmaceutical in the treatment of bone pain due to skeletal metastases from various cancers.
引用
- Yadav MP, Ballal S, Meckel M, et al. [177Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results. EJNMMI Res. 2020. PMID: 33113035. doi:10.1186/s13550-020-00709-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。